Page 7 - Bio Developments News Today

Swiss contract drug manufacturer Lonza has partnered with Oxford Nanopore to enhance the analysis of mRNA products.

Synthetic biology company Asimov has launched its new LV edge packaging system, which it claims will improve the cost efficiency and reduce the supply chain risk of lentiviral production.

The global messenger ribonucleic acid (mRNA) vaccine market currently consists entirely of vaccines for COVID-19.

Biotechnology company Vergent Bioscience has revealed that VGT-309, its investigational tumor-targeted fluorescent imaging agent, is able to help surgeons see lung tumors in real time during surgical procedures.

Genetic Design and Manufacturing Corporation (GDMC) has bagged $21 million in Series A funding to accelerate its next-gen advanced genetic therapies.

EUROAPI has joined forces with Swedish contract research organization (CRO) SpiroChem to offer its customers a consolidated CRO-CDMO solution.

We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.

We took the time to speak with Amy Walker, vice president at 4basebio, to discuss the merits of synthetic DNA and its future application.

We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.

Danish biotech company Vesper Bio has been awarded a grant worth $873,000 by The Michael J. Fox Foundation (MJFF) to assess sortilin inhibition in Parkinson’s disease.